Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Dyne Therapeutics, Inc. (DYN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-07-29
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $700.00K, a 75.86% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $400.00K, a 55.56% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $2.30M, a 67.14% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $500.00K, a 98.68% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $6.60M, a 92.69% decline from fiscal 2024.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $90.30M, a 1014.81% increase from fiscal 2023.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $8.10M, a 153.13% increase from fiscal 2022.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $3.20M, a 68.42% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $1.10M 10-Q · filed 2026-07-29 | $3.40M derived: sum of 3 quarters · filed 2026-07-29 | $3.90M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $400.00K 10-Q · filed 2026-05-11 | $2.70M derived: sum of 2 quarters · filed 2026-05-11 | $3.20M derived: sum of 3 quarters · filed 2026-05-11 | $6.10M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.80M derived: sum of 2 quarters · filed 2026-03-02 | $5.70M derived: sum of 3 quarters · filed 2026-07-29 | $6.60M 10-K · filed 2026-03-02 |
| 2025-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.40M derived: sum of 2 quarters · filed 2026-07-29 | $4.30M 10-Q · filed 2025-11-05 | $11.30M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $3.80M 10-Q · filed 2026-07-29 | $10.80M derived: sum of 3 quarters · filed 2026-07-29 | $48.70M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $900.00K 10-Q · filed 2026-05-11 | $7.90M derived: sum of 2 quarters · filed 2026-05-11 | $45.80M derived: sum of 3 quarters · filed 2026-05-11 | $58.70M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $44.90M derived: sum of 2 quarters · filed 2026-03-02 | $57.80M derived: sum of 3 quarters · filed 2026-03-02 | $90.30M 10-K · filed 2026-03-02 |
| 2024-09-30 | $37.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $50.80M derived: sum of 2 quarters · filed 2025-11-05 | $83.30M 10-Q · filed 2025-11-05 | $83.40M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $45.40M 10-Q · filed 2025-07-28 | $45.50M derived: sum of 3 quarters · filed 2026-03-02 | $46.50M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $32.50M 10-Q · filed 2025-05-08 | $32.60M derived: sum of 2 quarters · filed 2026-03-02 | $33.60M derived: sum of 3 quarters · filed 2026-03-02 | $38.40M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.10M derived: sum of 2 quarters · filed 2026-03-02 | $5.90M derived: sum of 3 quarters · filed 2026-03-02 | $8.10M 10-K · filed 2026-03-02 |
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.80M derived: sum of 2 quarters · filed 2024-11-12 | $8.00M 10-Q · filed 2024-11-12 | $10.80M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $7.00M 10-Q · filed 2024-08-12 | $9.80M derived: sum of 3 quarters · filed 2024-08-12 | $10.00M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $2.20M 10-Q · filed 2024-05-02 | $5.00M derived: sum of 2 quarters · filed 2024-05-02 | $5.20M derived: sum of 3 quarters · filed 2024-05-02 | $5.30M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $3.00M derived: sum of 2 quarters · filed 2024-03-05 | $3.10M derived: sum of 3 quarters · filed 2024-03-05 | $3.20M 10-K · filed 2024-03-05 |
| 2022-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $300.00K derived: sum of 2 quarters · filed 2023-10-30 | $400.00K 10-Q · filed 2023-10-30 | $700.00K derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $200.00K 10-Q · filed 2023-08-03 | $500.00K derived: sum of 3 quarters · filed 2023-08-03 | $2.00M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-11 | $400.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.90M derived: sum of 3 quarters · filed 2023-05-11 | $1.60M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.80M derived: sum of 2 quarters · filed 2023-03-02 | $1.50M derived: sum of 3 quarters · filed 2023-03-02 | $1.90M 10-K · filed 2023-03-02 |
| 2021-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.20M derived: sum of 2 quarters · filed 2022-11-03 | $1.60M 10-Q · filed 2022-11-03 | $1.21M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $100.00K 10-Q · filed 2022-08-04 | -$289.00K derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | $400.00K 10-Q · filed 2022-05-02 | $11.00K derived: sum of 2 quarters · filed 2022-05-02 | ||
| 2020-12-31 | -$389.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $200.00K 10-K · filed 2022-03-10 | ||
| 2020-09-30 | $589.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |